Patient-important outcomes in lung transplantation: A systematic review.

Adult Humans Lung Lung Transplantation Patient Reported Outcome Measures Prospective Studies Quality of Life
Lung transplantation Patient important outcomes Systematic review

Journal

Respiratory medicine and research
ISSN: 2590-0412
Titre abrégé: Respir Med Res
Pays: France
ID NLM: 101746324

Informations de publication

Date de publication:
May 2022
Historique:
received: 07 12 2021
revised: 07 02 2022
accepted: 12 02 2022
pubmed: 9 5 2022
medline: 22 6 2022
entrez: 8 5 2022
Statut: ppublish

Résumé

Patient-important outcomes (PIOs) have emerged in respiratory medicine, in order to place the patient at the center of research. Mortality is a debated PIO in lung transplantation (LTx). The use of PIO in this specific setting has never been studied. We aimed to systematically review the use of PIOs in LTx research. MEDLINE, Cochrane Library and Embase databases were searched to include prospective studies published in 2019, involving adult LTx recipients. We excluded articles reporting non-prognostic studies, letters, reviews, commentaries, or case reports. PIOs considered were mortality, pain, physical function, pulmonary, gastrointestinal, neuropsychological, cardiac, sleep or sexual symptoms and quality of life. This systematic review was prospectively registered in the PROSPERO register (CRD42020163425). Among 1048 references retrieved, 51 were finally included in the analysis. In total, 26 (51%) studies investigated at least one PIO, as a primary outcome in 12 (23.5%) and secondary outcome in 21 (41.2%). In 15 (29.4%) studies, mortality was the most frequently reported PIO; 11 (21.5%) studies evaluated at least one PIO other than mortality, quality of life being this PIO in 6. PIOs were described in half of prospective articles dealing with adult LTx recipients published in 2019. Outcomes other than mortality were insufficiently considered. A core outcome set of PIOs in LTx should be developed with patient input to guide future research in LTx.

Sections du résumé

BACKGROUND BACKGROUND
Patient-important outcomes (PIOs) have emerged in respiratory medicine, in order to place the patient at the center of research. Mortality is a debated PIO in lung transplantation (LTx). The use of PIO in this specific setting has never been studied. We aimed to systematically review the use of PIOs in LTx research.
METHODS METHODS
MEDLINE, Cochrane Library and Embase databases were searched to include prospective studies published in 2019, involving adult LTx recipients. We excluded articles reporting non-prognostic studies, letters, reviews, commentaries, or case reports. PIOs considered were mortality, pain, physical function, pulmonary, gastrointestinal, neuropsychological, cardiac, sleep or sexual symptoms and quality of life. This systematic review was prospectively registered in the PROSPERO register (CRD42020163425).
RESULTS RESULTS
Among 1048 references retrieved, 51 were finally included in the analysis. In total, 26 (51%) studies investigated at least one PIO, as a primary outcome in 12 (23.5%) and secondary outcome in 21 (41.2%). In 15 (29.4%) studies, mortality was the most frequently reported PIO; 11 (21.5%) studies evaluated at least one PIO other than mortality, quality of life being this PIO in 6.
CONCLUSIONS CONCLUSIONS
PIOs were described in half of prospective articles dealing with adult LTx recipients published in 2019. Outcomes other than mortality were insufficiently considered. A core outcome set of PIOs in LTx should be developed with patient input to guide future research in LTx.

Identifiants

DOI: 10.1016/j.resmer.2022.100896 PMID: 35526317
pubmed: 35526317
pii: S2590-0412(22)00013-7
doi: 10.1016/j.resmer.2022.100896
pii:
doi:

Types de publication

Journal Article Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

100896

Informations de copyright

Copyright © 2022 SPLF and Elsevier Masson SAS. All rights reserved.

Déclaration de conflit d'intérêts

Declarations of interest GW received consulting fees from CSL Behring; VB received advisory board fees from Novartis and Takeda; AR received a grant support from “Fondation du Souffle”, consulting fees and honoraria from Biotest; PhM received lecture honoraria and board fees from Pfizer, MSD and Menarini; JM received congress reimbursement fees from Fisher&Paykel and CSLBehring. CG, PiM, YC, NG, HM, ATD, SG declared no competing interest.

Auteurs

Gaëlle Weisenburger (G)

Service de Pneumologie B et Transplantation Pulmonaire, APHP.Nord-Université de Paris, Hôpital Bichat-Claude Bernard, Paris, France; Physiopathology and Epidemiology of Respiratory Diseases, UMR1152 INSERM and Université de Paris, Paris, France.

Nathalie Gault (N)

INSERM CIC-EC1425, Hôpital Bichat, Paris, France; APHP, département Epidémiologie Biostatistiques et Recherche Clinique, Hôpital Bichat, Paris, France.

Antoine Roux (A)

Pneumology, Adult Cystic Fibrosis Center and Lung Transplantation Dept, Foch Hospital, Suresnes, France; Université Versailles-Saint-Quentin-en-Yvelines, Versailles, France; Paris Transplant Group, Paris, France.

Alexy Tran-Dinh (A)

Département d'Anesthésie et Réanimation, APHP.Nord-Université de Paris, Hôpital Bichat-Claude Bernard, Paris, France; Laboratory for Vascular Translational Science, UMR1148, INSERM and Université de Paris, Paris, France.

Vincent Bunel (V)

Service de Pneumologie B et Transplantation Pulmonaire, APHP.Nord-Université de Paris, Hôpital Bichat-Claude Bernard, Paris, France; Physiopathology and Epidemiology of Respiratory Diseases, UMR1152 INSERM and Université de Paris, Paris, France.

Cendrine Godet (C)

Service de Pneumologie B et Transplantation Pulmonaire, APHP.Nord-Université de Paris, Hôpital Bichat-Claude Bernard, Paris, France; Physiopathology and Epidemiology of Respiratory Diseases, UMR1152 INSERM and Université de Paris, Paris, France.

Pierre Mordant (P)

Physiopathology and Epidemiology of Respiratory Diseases, UMR1152 INSERM and Université de Paris, Paris, France; Service de Chirurgie Vasculaire, Thoracique et Transplantation, APHP.Nord-Université de Paris, Hôpital Bichat-Claude Bernard, Paris, France.

Philippe Montravers (P)

Département d'Anesthésie et Réanimation, APHP.Nord-Université de Paris, Hôpital Bichat-Claude Bernard, Paris, France; Laboratory for Vascular Translational Science, UMR1148, INSERM and Université de Paris, Paris, France.

Yves Castier (Y)

Physiopathology and Epidemiology of Respiratory Diseases, UMR1152 INSERM and Université de Paris, Paris, France; Service de Chirurgie Vasculaire, Thoracique et Transplantation, APHP.Nord-Université de Paris, Hôpital Bichat-Claude Bernard, Paris, France.

Hervé Mal (H)

Service de Pneumologie B et Transplantation Pulmonaire, APHP.Nord-Université de Paris, Hôpital Bichat-Claude Bernard, Paris, France; Physiopathology and Epidemiology of Respiratory Diseases, UMR1152 INSERM and Université de Paris, Paris, France.

Stéphane Gaudry (S)

Département de réanimation médico-chirurgicale, APHP Hôpital Avicenne, Université Sorbonne Paris Nord, Bobigny, France; Common and Rare Kidney Diseases, French National Institute of Health and Medical Research, INSERM UMR_S 1155, Sorbonne Université, Paris, France; Health Care Simulation Center, UFR SMBH Université Sorbonne Paris Nord, Bobigny, France.

Jonathan Messika (J)

Service de Pneumologie B et Transplantation Pulmonaire, APHP.Nord-Université de Paris, Hôpital Bichat-Claude Bernard, Paris, France; Physiopathology and Epidemiology of Respiratory Diseases, UMR1152 INSERM and Université de Paris, Paris, France; Paris Transplant Group, Paris, France. Electronic address: jonathan.messika@aphp.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Patient-important outcomes in lung...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Patient-important outcomes in lung...
questionsmedicales.fr › Appareil respiratoire › Poumon › Patient-important outcomes in lung...
questionsmedicales.fr › Procédures de chirurgie opératoire › Transplantation › Transplantation d'organe › Transplantation pulmonaire › Patient-important outcomes in lung...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Collecte de données › Enquêtes et questionnaires › Enquêtes sur les soins de santé › Mesures des résultats rapportés par les patients › Patient-important outcomes in lung...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études prospectives › Patient-important outcomes in lung...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Mesures épidémiologiques › Démographie › État de santé › Qualité de vie › Patient-important outcomes in lung...